Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study | Synapse
March 3, 2026Open Access
Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study
Puntos clave
The quadrivalent meningococcal conjugate vaccine shows significant immunogenicity in participants aged 56 and older, ensuring robust protection against meningococcal disease.
Safety assessments reveal that the vaccine is well-tolerated with minimal adverse effects, promoting confidence among older pilgrims during travel.
This open-label study utilizes a Phase III design, confirming the vaccine's efficacy in a real-world population of potential Hajj participants.
The findings support the inclusion of the vaccine in immunization schedules for older travelers to high-risk areas, particularly during Hajj and Umrah.